Liquid biopsy in prostate cancer: A multidisciplinary expert consensus statement
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Introduction BRCA1/2 testing via liquid biopsy has emerged as a critical, minimally invasive alternative to tissue sampling in metastatic castration-resistant prostate cancer (mCRPC), especially in the context of insufficient, inadequate, or unavailable tumor material. Methods A multidisciplinary panel of 18 Italian experts from 16 leading academic and clinical institutions convened to develop consensus recommendations on BRCA1/2 testing via liquid biopsy. Through virtual and on-site meetings, technical gaps in pre-analytical, analytical, and post-analytical workflows were identified and addressed. Statements were approved by ⩾80% of panelists and reviewed to reflect both current evidence and expert practice. Results The survey confirmed widespread implementation or imminent adoption of liquid biopsy testing across Italian centers, despite persistent challenges in standardizing sample collection, testing management, preservation, and reporting. Key technical insights included the importance of cfDNA-preserving tubes, optimal storage conditions, assay sensitivity (LoD <1.0%), and bioinformatic integration for detecting low-frequency variants. Next-generation sequencing was unanimously preferred, with BRCA1/2 coverage extended to coding and flanking regions. A harmonized synoptic report structure was proposed to enhance clinical interpretability and facilitate oncologic decision-making. Conclusions Despite limitations in tissue availability, the integration of liquid biopsy into a diagnostic algorithm, endorsed by both AIOM and ESMO guidelines, enables broader access to BRCA1/2 stratification and supports timely PARP inhibitor therapy. This consensus aims to improve diagnostic consistency and clinical outcomes in the management of mCRPC across Italy.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Liquid biopsy in prostate cancer: A multidisciplinary expert consensus statement
- Date Crossref
- 29/09/2025
- Éditeur
- SAGE Publications
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Naples Federico II Department of Public Health pays non établi dans la noticeUniversité ou école supérieure
-
University of Milano-Bicocca Department of Medicine and Surgery pays non établi dans la noticeUniversité ou école supérieure
-
Centro di Riferimento Oncologico pays non établi dans la noticeÉtablissement de santé
-
Ospedale Policlinico San Martino Hereditary Tumors Unit pays non établi dans la noticeÉtablissement de santé
-
Azienda USL di Bologna pays non établi dans la noticeÉtablissement de santé
-
University of Bologna Department of Pharmacy and Biotechnology (FaBit) pays non établi dans la noticeUniversité ou école supérieure
-
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino pays non établi dans la noticeÉtablissement de santé
-
University of Milan pays non établi dans la noticeUniversité ou école supérieure
-
European Institute of Oncology IEO pays non établi dans la noticeÉtablissement de santé
-
Istituti di Ricovero e Cura a Carattere Scientifico pays non établi dans la noticeÉtablissement de santé
-
Agostino Gemelli University Polyclinic pays non établi dans la noticeÉtablissement de santé
-
Istituto Oncologico Veneto pays non établi dans la noticeÉtablissement de santé
Department of Public Health — University of Naples Federico II, Department of Medicine and Surgery — University of Milano-Bicocca et Centro di Riferimento Oncologico, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.